Cynosure, Inc. (NASDAQ:CYNO) was the target of a significant decrease in short interest during the month of January. As of February 28th, there was short interest totalling 864,031 shares, a decrease of 26.9% from the February 14th total of 1,181,243 shares, StockRatingsNetwork reports. Approximately 4.3% of the shares of the stock are sold short. Based on an average trading volume of 370,045 shares, the days-to-cover ratio is presently 2.3 days. Cynosure, Inc. (NASDAQ:CYNO) shares after opening at $30.00 moved to $30.31 on last trade day and at the end of the day closed at $29.33. Company price to sales ratio in past twelve months was calculated as 2.86 and price to cash ratio as 5.38. Cynosure, Inc. (NASDAQ:CYNO) showed a negative weekly performance of -3.61%.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) manages to remain in the news for the right reasons. The stock of the company continues its northward rise after reports that the company may launch some products in the U.S. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) shares fell -3.08% in last trading session and ended the day on $5.66. OCLS return on equity ratio is recorded as -208.50% and its return on assets is -58.20%. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) yearly performance is 92.52%.
The Palatin Technologies, Inc. (NYSEMKT:PTN) offers pharmaceuticals for unmet medical needs in chronic illnesses. The stock has moved up by 83.47% in the last 1 year. In te recently reported quarter that ended Dec, 2013 the company earned a net loss while the comparable quarter of last year was profitable. Despite a loss making quarterly operation steh company’s stock received a rating upgrade owing to its strong foothold in its business segment and its all inclusive product-line melanocortin. Palatin Technologies, Inc. (NYSEMKT:PTN) shares moved up 15.60% in last trading session and was closed at $1.26, while trading in range of $1.09-$1.28. Palatin Technologies, Inc. (NYSEMKT:PTN) year to date performance is 72.60%.
Barclays assumed coverage on shares of Durata Therapeutics Inc (NASDAQ:DRTX) in a report issued on Tuesday,StockRatingsNetwork reports. The firm issued a buy rating and a $13.91 target price on the stock. Durata Therapeutics Inc (NASDAQ:DRTX) weekly performance is 13.73%. On last trading day company shares ended up $16.65. Durata Therapeutics Inc (NASDAQ:DRTX) distance from 50-day simple moving average is 29.69%. Analysts mean target price for the company is $15.93.